There were 1,783 press releases posted in the last 24 hours and 442,635 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Loxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion Proteins

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image